Pulmonx CCO sells 7,879 shares at $2.26

Pulmonx’s chief commercial officer sold shares to cover RSU-related tax withholding, not as discretionary open-market sales.

Rhea-AI Filing Summary

Pulmonx Corp (LUNG) reported that Chief Commercial Officer Rose Geoffrey Beran sold a total of 7,879 shares of common stock on September 1, 2026, in four open-market transactions at $2.26 per share. Footnotes state each sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023, 2024, 2025, and 2026. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 7,879 shares

Net Sell 4 txns

Insider Rose Geoffrey Beran

Role Chief Commercial Officer

Sold 7,879 shs ($18K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,213	$2.26	$5K
Sale	Common Stock F2	2,390	$2.26	$5K
Sale	Common Stock F3	1,530	$2.26	$3K
Sale	Common Stock F4	1,746	$2.26	$4K

Holdings After Transaction: Common Stock — 449,832 shares (Direct)

Footnotes (4)

1. F1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 2, 2026.
2. F2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
3. F3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
4. F4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.

Key Figures

Total shares sold: 7,879 shares Sale price per share: $2.26 per share Number of sale transactions: 4 transactions +1 more

4 metrics

Total shares sold 7,879 shares Common stock sold by Rose Geoffrey Beran on September 1, 2026

Sale price per share $2.26 per share Price for each of the four reported sale transactions

Number of sale transactions 4 transactions Open-market or private sales of common stock on September 1, 2026

RSU grant dates linked to tax sales 4 grant dates RSUs granted on March 1, 2023; March 1, 2024; March 3, 2025; March 2, 2026

Key Terms

Restricted Stock Units, tax withholding obligations, vesting

3 terms

Restricted Stock Units financial

"in connection with the vesting of the Restricted Stock Units (the "RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the reporting person to cover tax withholding obligations in connection"

vesting financial

"to cover tax withholding obligations in connection with the vesting of the RSUs"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pulmonx Corp (LUNG) disclose for Rose Geoffrey Beran?

Pulmonx Corp disclosed that Chief Commercial Officer Rose Geoffrey Beran sold 7,879 shares of common stock on September 1, 2026 in four open-market transactions at $2.26 per share each.

Why did the Pulmonx (LUNG) executive sell 7,879 shares on September 1, 2026?

The filing states that all reported shares were sold to cover tax withholding obligations associated with the vesting of RSUs granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026.

Were the Pulmonx (LUNG) insider sales made under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not checked, and the footnotes do not reference any trading plan, so the transactions are not reported as being under a Rule 10b5-1 plan.

What price did the Pulmonx (LUNG) insider receive for the sold shares?

Each of the four transactions reports a price of $2.26 per share for Pulmonx common stock on September 1, 2026, characterized as sales in the open market or a private transaction.

How many Pulmonx (LUNG) transactions were reported and what types of shares were involved?

The Form 4 reports four separate transactions, each a sale of Common Stock. All are non-derivative transactions and together total 7,879 shares sold on September 1, 2026.

Do we know how many Pulmonx (LUNG) shares the executive holds after these sales?

No. For each transaction, the "shares following transaction" field is null, so the filing does not state the executive’s remaining Pulmonx common stock holdings after these sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:20 PM EDT Accepted by SEC EDGAR 09/03/2026 - 06:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rose Geoffrey Beran

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		2,213	D	$2.26	455,498	D
Common Stock	09/01/2026		S(2)		2,390	D	$2.26	453,108	D
Common Stock	09/01/2026		S(3)		1,530	D	$2.26	451,578	D
Common Stock	09/01/2026		S(4)		1,746	D	$2.26	449,832	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 2, 2026.

2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.

3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.

4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.

	/s/ David Aaron Lehman, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)